Skip to Content
Merck
CN

SML3285

Apixaban

≥98% (HPLC), powder, Factor Xa (FXa) inhibitor

Synonym(s):

1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-Tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, BMS 562247, BMS-562247, BMS562247

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C25H25N5O4
CAS Number:
503612-47-3
Molecular Weight:
459.50
UNSPSC Code:
12352107
NACRES:
NA.77
MDL number:
MFCD11977295

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Apixaban, ≥98% (HPLC)

SMILES string

N5(CCCCC5=O)c1ccc(cc1)N2CCc3c([n](nc3C(=O)N)c4ccc(cc4)OC)C2=O

InChI

1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)

InChI key

QNZCBYKSOIHPEH-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Quality Level

100

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Apixaban is an orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor (human/rabbit Ki = 0.08/0.17 nM; trypsin Ki >3 μM) with good anticoagulant activity in vitro (EC2x = 3.8 μM by prothrombin time (PT) assay, 5.1 μM by activated partial thromboplastin time (aPTT) assay) and antithrombotic efficacy in vivo (IC50 = 329 nM i.v. by rabbit arteriovenous shunt model).
Orally active, active site-targeting, highly potent and selective factor Xa (FXa) inhibitor with antithrombotic efficacy in vitro and in vivo.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000499685
0000499685
0000478630
0000478630
0000438639

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

P L A Giesen et al.
Thrombosis journal, 19(1), 60-60 (2021-08-30)
Thrombin generation (TG) assessed by Calibrated Automated Thrombogram (CAT-I) reflects the overall capacity of plasma to generate thrombin, thus evaluating the balance between the anti- and procoagulant processes. However, with this method the calibrator curve is usually not measured until
P C Wong et al.
Journal of thrombosis and haemostasis : JTH, 6(5), 820-829 (2008-03-05)
Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late-stage clinical development for the prevention and treatment of thromboembolic diseases. We evaluated the in vitro properties of apixaban and its in vivo activities in rabbit models
P C Wong et al.
Journal of thrombosis and haemostasis : JTH, 6(10), 1736-1741 (2008-07-24)
Optimal treatment of arterial thrombosis may include a combination of antiplatelet and anticoagulant drugs. We evaluated apixaban, a direct and highly selective factor Xa inhibitor, in combination with clinically relevant doses of aspirin and/or clopidogrel for prevention of arterial thrombosis
Donald J P Pinto et al.
Journal of medicinal chemistry, 50(22), 5339-5356 (2007-10-05)
Efforts to identify a suitable follow-on compound to razaxaban (compound 4) focused on modification of the carboxamido linker to eliminate potential in vivo hydrolysis to a primary aniline. Cyclization of the carboxamido linker to the novel bicyclic tetrahydropyrazolopyridinone scaffold retained
Noelle D Herrera et al.
Frontiers in veterinary science, 8, 702821-702821 (2021-07-23)
Thrombosis is common in critically ill dogs and causes considerable morbidity and mortality. The direct factor Xa inhibitor apixaban is safe, efficacious, and convenient in humans. This study aimed to determine the pharmacokinetics (PK), bioactivity, protein binding, and bioavailability of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service